For International Physicians: Refractory angina is often not the end of the road. It’s about understanding the underlying mechanisms and identifying patients who do have new therapeutic options. Despite optimal therapy, many patients continue to experience debilitating symptoms. Innovative approaches like the #ShockwaveReducer# are helping redefine what’s possible. This was a key theme in the discussion between Dr Tim van de Hoef (@drTPH) and Dr Tommaso Gori (@tommasoggori) at EuroPCR 2026, highlighting the importance of better patient identification and how a shift in perspective can open new possibilities, including the #ShockwaveReducer#. Watch the video to explore how the understanding of refractory angina is evolving and why it may not be as “refractory” as we think: Safety info link in Bio. CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.